French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance

Prog Urol. 2022 Nov;32(15):1373-1419. doi: 10.1016/j.purol.2022.07.147.

Abstract

Objective: The objective of the French Urology Association Cancer Committee is to propose an update of the recommendations for the management of prostate cancer.

Methods: A systematic review of the literature from 2020 to 2022 was conducted by the CCAFU on the elements of therapeutic management of metastatic and castration-resistant prostate cancer (PC), while evaluating the references and their levels of evidence.

Results: Androgen deprivation therapy (ADT) remains the standard treatment for metastatic prostate cancer. ADT intensification is now a standard of care in the management of metastatic prostate cancer. This intensification is discussed in relation to the patient and the characteristics of the disease. For all metastatic hormone-sensitive PC (synchronous and metachronous), the overall survival benefit associated with good tolerability makes the combination of ADT and novel hormonal agents (NHA) a standard. For patients with high-volume/high-risk de novo metastatic disease, treatment with docetaxel in addition to ADT + NHA can be discussed for eligible patients. In patients with castration-resistant prostate cancer (CRPC), the contribution of new therapies that have become available in recent years, as well as the advent of precision medicine, help to improve the control of tumour progression and survival, and highlight the value of testing for alterations in DNA repair genes within the tumour tissue or constitutionally.

Conclusion: This update of the French recommendations should help to improve the management of patients with prostate cancer.

Keywords: Cancer de la prostate; Diagnosis; Diagnostic; Guidelines; Prostate cancer; Recommandations; Traitement; Treatment.

Publication types

  • Review
  • Practice Guideline

MeSH terms

  • Androgen Antagonists* / therapeutic use
  • Castration
  • Docetaxel / therapeutic use
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy

Substances

  • Androgen Antagonists
  • Docetaxel